Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1Completed 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Gemcitabine 9Docetaxel 5Mitomycin 4erdafitinib 3durvalumab 3Cystoscopy 3disitamab vedotin 2BCG Vaccine 25-aminolevulinic acid hexyl ester 2tremelimumab 1tislelizumab 1monalizumab 1dodecyl maltoside 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Therapeutic Uses 1Surveys and Questionnaires 1Saline Solution 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Monatide (IMS 3015) 1Mitozytrex 1Metformin 1Magnetic Resonance Spectroscopy 1Laser Therapy 1Hyaluronic Acid 1House Calls 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Muscle Invasive Bladder Neoplasms × dodecyl maltoside × Clear all
NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡